NeuroPace raises 2026 revenue guidance to $99.5 million to $101.5 million
NeuroPace reported second quarter 2026 revenue of $22.8 million, up 17% from $19.5 million a year earlier, and its net loss narrowed to $6.2 million from $10.0 million. The company raised its full-year 2026 total revenue guidance and its Adjusted EBITDA loss outlook, which may matter to shareholders because it signals stronger expected sales and a smaller expected loss for the year.
Key points
- Q2 2026 total revenue was $22.8 million, up 17% from $19.5 million in Q2 2025; RNS System revenue rose 21.3% to $22.5 million.
- Q2 2026 net loss was $6.2 million, compared with $10.0 million in Q2 2025 (continuing operations).
- Full-year 2026 total revenue guidance was raised to $99.5 million to $101.5 million from $99 million to $101 million.
- Full-year 2026 Adjusted EBITDA guidance was raised to a loss of $7.5 million to $8.5 million from a loss of $8.5 million to $9.5 million.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.